Compare ADMA Biologics Inc (ADMA) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.69. The key difference: Roundhill Innov-100 0DTE Covered Call Strat ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | QDTE | |
|---|---|---|
Market Cap | $2.18B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $20.38 | $36.60 |
52-Week Low | $7.60 | $26.85 |
Enterprise Value | $2.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
QDTE trades at $29.69 with a 1.19% daily gain, but technical indicators signal bearish momentum with resistance at $30. The ETF faces fundamental concerns as its high distribution yield appears funded by return of capital rather than organic earnings, potentially eroding NAV over time. Recent news highlights growing skepticism about the sustainability of its 24% yield strategy.
Outlook remains cautious due to structural yield concerns and NAV erosion risks. While weekly distributions attract income seekers, the fund's reliance on return of capital poses significant long-term value destruction risks. Investors should weigh high current income against potential principal erosion in volatile market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
